Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea

on the continent is troubling, given the lack of alternative treatments.

that result in variable performance of histidine rich protein 2 (HRP2)-based rapid diagnostic tests for malaria.

R622I mutation, which made them potentially undetectable by HRP2-based rapid diagnostic tests.

in Eritrea threaten to compromise regional malaria control and elimination campaigns. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry numbers, ACTRN12618001223224, ACTRN12618000353291, and ACTRN12619000859189.).